Stock Detail
ANGIOTECH PHARMACEUTICALS INC - COMMON SHARES
Drug Manufacturers Other
ANPI @ Yahoo Finance | ANPI Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $0.21 | $0.21 | $0.00 | 0.00% | 0.00 | $0.21 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $0.00 | $0.00 | 0 | 1.45M | 2.93M | -0.33 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 0.35 | 0.28 | 0.14 | 0.07 | -0.07 |
Stock Profile
Angiotech Pharmaceuticals, Inc. focuses on combining pharmaceutical compounds with medical devices and biomaterials to address common complications associated with certain surgical procedures and processes of various diseases worldwide. It primarily sells coronary stent systems incorporating the drug paclitaxel for the treatment of coronary artery disease. The company's other commercial products include VITAGEL surgical hemostat, a bioresorbable hemostatic material used to reduce patient blood loss during surgical procedures; CoSeal surgical sealant, a biomaterial surgical sealant used to enable tissue repair and regeneration; Collagraft and NeuGraft, collagen-based biomaterial products for orthopaedic and spinal surgery applications; and various polymeric biocompatible coatings for medical devices. Angiotech's ongoing clinical programs include TAXUS Liberte, Vascular Wrap, Adhibit, and Peripheral Drug Eluting Stent Program. TAXUS Liberte is a paclitaxel eluting coronary stent system to treat restenosis, and other local inflammatory and proliferative diseases. Vascular Wrap is used to prevent stenosis following vascular bypass surgery in the limbs. Adhibit adhesion prevention gel, a nondrug-loaded biomaterial product, is undergoing human clinical studies in Europe. Peripheral Drug Eluting Stent Program is a study of a paclitaxel-eluting stent to treat peripheral artery disease in the limbs. In addition, the company has other preclinical programs, including anti-infective central venous catheter program and intra-articular paclitaxel program for the prevention of post injury contractures and cartilage preservation. Angiotech has a strategic alliance with Baxter Healthcare Corporation and CombinatoRx. Angiotech was incorporated in 1989. The company was formerly known as Holwest Industries, Ltd. It changed its name to Angiogenesis Technologies, Inc. in 1992 and to Angiotech Pharmaceuticals, Inc. in 1996. The company is headquartered in Vancouver, Canada.